Earlier this week, I discussed Clínica 0-19, a clinic “making DIPG history in Monterrey” whose doctors claim to be able to successfully treat the deadly brainstem cancer DIPG using intra-arterial chemotherapy and immunotherapy. This week, I discuss what I’ve learned since last week, specifically a lot more about just what it is that these doctors do, why it is scientifically dubious and unproven, and why I am becoming even more harsh in my assessment of this clinic, which shows every indication of being a predatory clinic selling an unproven treatment for a very high price.
Search: “"Stanislaw Burzynski"”
We found 388 results for your search.
Drs. Alberto Siller and Alberto Garcia run Clínica 0-19 in Monterrey, Mexico, which has become a magnet for patients with diffuse intrinsic pontine glioma (DIPG), a deadly brain cancer. Unfortunately, their treatment is an unproven combination of 11 chemotherapy drugs injected into an artery feeding the brainstem, plus an unknown and unproven “immunotherapy.” Of course it all costs $300,000 or more for a complete course of treatment, and the good doctors are “too busy to do clinical trials” or even publish their survival and recurrence statistics, despite having used this protocol for 20 years. I say: If it quacks like a duck…
Last week, we learned that antivaccine pediatrician Dr. Bob Sears was disciplined by the Medical Board of California. It didn’t take long for him to take to Facebook to make excuses and paint himself as a martyr to the “vaccine freedom” cause or for his antivaccine admirers to come up with ridiculous conspiracy theories.
I warned you. I’ve been warning you for four years. Now that a federal right-to-try law has passed, the profiteering has begun. Let patients beware!
On Wednesday, President Trump signed a federal right-to-try bill into law with great fanfare, making extravagant claims for it. It’s time to reiterate one last time that right-to-try will not help terminally ill patients but it will strip important protections from them. It’s pure snake oil.
